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Open access under CC BY-NC-ND license.The identification and validation of biomarkers for diag-
nosing Alzheimer’s disease (AD) and other forms of
dementia are increasingly important. To date, ELISA
measurement of b-amyloid(1–42), total tau and phos-
pho-tau-181 in cerebrospinal fluid (CSF) is the most
advanced and accepted method to diagnose probable
AD with high specificity and sensitivity. However, it is a
great challenge to search for novel biomarkers in CSF
and blood by using modern potent methods, such as
microarrays and mass spectrometry, and to optimize the
handling of samples (e.g. collection, transport, proces-
sing, and storage), as well as the interpretation using
bioinformatics. It seems likely that only a combined
analysis of several biomarkers will define a patient-spe-
cific signature to diagnose AD in the future.
Diagnosing Alzheimer’s disease (AD) and other forms of
dementia
AD is a severe neurodegenerative disorder of the brain that
is characterizedby loss ofmemoryandcognitivedecline.The
majority of AD cases are sporadic (risk age >60 years), and
<2.5% have a genetic disposition. It is estimated that in
2050, approximately 80 million people will suffer from AD
worldwide. Thus, it is a great challenge to establish reliable
surrogatemarkers to diagnose andmonitor disease progres-
sion. Definitive diagnosis requires both clinical assessment
of the disease and post-mortem verification of the AD pa-
thology (plaques and tangles). A probable diagnosis of AD
can be established with a confidence of >90%, based on
clinical criteria, including medical history, physical exami-
nation, laboratory tests, neuroimaging and neuropsycholog-
ical evaluation. Accurate, early diagnosis of AD is still
difficult because early symptoms of the disease are shared
by a variety of disorders, which reflects common neuropath-
ological features. An ideal biomarker would distinguish AD
from other types of dementia, such as mild cognitive im-
pairment (MCI), or mixed forms of dementia, such as vas-
cular dementia (VaD), frontotemporal lobe dementia
(FTLD), or Lewy body dementia (LBD). This is important
because treatment for these diseases might differ.
What is a biomarker?
A biological marker, or biomarker [1–5], is objectively
measured and evaluated as an indicator of normal biologi-
cal processes, pathogenic processes or pharmacological
responses to a therapeutic intervention. A biomarkerCorresponding author: Humpel, C. (christian.humpel@i-med.ac.at).
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and disease. The sensitivity, specificity and ease-of-use are
the most important factors that ultimately define the
diagnostic utility of a biomarker. Some biomarkers are
more reasonably viewed as risk factors rather than true
disease markers. In order for a diagnostic biomarker to be
useful, certain criteria must be met (Box 1) [6–9].
Biomarkers for AD in cerebrospinal fluid (CSF)
Three biomarkers have been well-established and validat-
ed internationally to diagnose AD in CSF with ELISAs: b-
amyloid(1–42) [Ab(1–42)], total tau and phospho-tau-181.
It is now the consensus that only the combination of these
three CSF biomarkers significantly increases the diagnos-
tic validity for sporadic AD, which yields a combined
sensitivity of >95% and a specificity of >85% [10–13].
Ab(1–42)
AD is characterized by extracellular Ab plaque depositions.
Ab is cleaved from the large amyloid-precusor protein (APP)
by secretases, and processing of amyloidogenic pathways
produces a 42-amino-acid peptide [Ab(1–42)] that can ag-
gregate in the brain under certain conditions (e.g. acidosis,
metals).AnalysisofCSFAb(1–42) showsahighlysignificant
reduction inADpatients compared to controls,with a cut-off
of<500 pg/ml (Table 1). It has been suggested that reduced
levels of Ab(1–42) in the CSF are caused by reduced clear-
ance of Ab from the brain to the blood/CSF, as well as
enhanced aggregation and plaque deposition in the brain.
Changes in CSFAb levels differ based on the disease (Table
2) [14–16]. For example, decreasedAb(1–38) levels correlate
with FTLD, and Ab(1–37) levels with LBD [4]. CSF levels of
shorterAb(1–40) formsareunchangedor increased inAD. It
has therefore been suggested that the Ab42/Ab40 ratio can
improve AD diagnosis, but others have not found such
changes [17,18]. Novel detection methods allow measure-
ment of Ab oligomers, which might improve the diagnostic
specificity. As an example, surface-enhanced laser desorp-
tion/ionization-time-of-flight-mass spectrometry (SELDI-
TOF-MS) (Table 3) has emerged as an ideal method for
the simultaneous detection and quantitation of a variety of
Ab peptide cleavage products [19].
Total tau
The second hallmark of AD are intraneuronal inclusions of
themicrotubule-associated protein tau. In healthy controls,
levels of total tau in theCSF increasewith age [20]:<300pg/
ml (21–50 years),<450 pg/ml (51–70 years), and<500 pg/ml.2010.09.007 Trends in Biotechnology, January 2011, Vol. 29, No. 1
Box 1. Criteria for establishing a good biomarker for the
diagnosis of dementia
 Reflect physiological aging processes
 Reflect basic pathophysiological processes of the brain
 React upon pharmacological intervention
 Display high sensitivity
 Display high specificity for the disease as compared with related
disorders
 Allow measurements repeatedly over time
 Allow reproducibility in laboratories worldwide
 Should be measurable in noninvasive, easy-to-perform tests
 Should not cause harm to the individuals being assessed
 Tests should be inexpensive and rapid
 Samples should be stable to allow easy and cheap transport
 Easy collection of fluids not only in hospitals
 Changes should be at least twofold to allow differentiation of
controls
 Define good cut-off values to distinguish diseases
 Data published in peer-reviewed journals
 Data reproduced by at least two independent researchers
Table 1. Internationally established biomarkers in CSF used to
diagnose ADa
Biomarker Controls (pg/ml) AD (pg/ml)
Ab(1–42) 79420 <500*
Total tau 13689 (21–50 years) b
243127 (51–70 years) >450
341171 (>71 years) >600*
Phospho-tau-181 232 >60*
aData obtained using the Innogenetics single 96-well ELISA kits.
bThis is not relevant for sporadic AD, because it is only for patients>60 years of age.
*P<0.001
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ADpatients as comparedwith age-matched control subjects
with a cut off of >600 pg/ml (Table 1). Total tau levels are
dramatically enhanced in Creutzfeldt–Jacob disease (CJD)
(>3000 pg/ml). Tau levelsmight also be a prognosticmarker
with a good predictive validity for conversion from MCI to
AD, because high CSF tau level has been found in 90% of
MCI cases that later progressed to AD, but not in caseswith
stableMCI [10]. Observed changes inCSF total tau level for
different diseases are shown in Table 2 [14].
Phosphorylated tau
Tau is markedly hyperphoshorylated (39 possible sites) in
AD, which results in a lack of function and axonal trans-
port dysfunction. The detection of tau phosphorylated at
position 181 is significantly enhanced in AD compared to
controls [21], with a cut-off of >60 pg/ml (Table 1). TheTable 2. Changes in the levels of established CSF biomarkers in
different central nervous system diseases
Disease Ab(1–42) Total tau Phospho-tau-181
Acute stroke – "(") –
Alcohol dementia – – –
AD # " "
CJD ## """ –
Depression – – –
FTLD # " –
LBD # " "
Neuroinflammation # – –
Normal aging – – –
Parkinson’s disease – – –
VaD #(#) " –
aModified according to Ref. [14]: (–), no change; (#), decrease; ("), increase.changes of CSF phospho-tau-181 levels in different dis-
eases are given in Table 2 [14]. The analysis of other
phosphorylated forms of tau (phospho-tau-199, -231,
-235, -396 and -404) might offer significant improvements
towards early diagnosis of AD [11]. Phospho-tau-231 and
phospho-tau-181 can be used to distinguish AD from con-
trols and FTLD, LBD, VaD and major depression [4,21].
Furthermore, the concentration of phospho-tau-231 has
shown longitudinal decline from mild to moderate AD
[21]. It is a high priority to develop specific and sensitive
ELISAs for other site-specific phosphorylated tau isoforms
to improve the diagnostic repertoire for AD.
Other CSF biomarkers
Despite strong efforts to characterize other potential bio-
markers in CSF, several biomarkers have been tested in
CSF that have displayed changes between AD and controls
[4,22,23]. However, no other single biomarker has been
validated to date for routine diagnosis, because the
changes are very heterogeneous and low, and data have
differed between laboratories. Cognitive decline is highly
correlated with loss of the neurotransmitter acetylcholine
in the cortex or the hippocampus. Degeneration of cholin-
ergic neurons can be prevented by application of nerve
growth factor (NGF), which has been found to be reproduc-
ibly increased in CSF of AD patients [22–24]; however,
such low changes are not yet useful for establishingNGF as
a biomarker. The use of mass spectrometry (MS) methods
or different microarrays (Table 3) might rapidly increase
the knowledge on disease-related changes to uncover novel
biomarkers in CSF of AD patients.
Biomarkers in blood
The routine diagnosis of AD and mixed forms of dementia
from CSF has several drawbacks: lumbar puncture and
collection of CSF is an invasive treatment with potential
side effects, and screening of patients is often difficult and
follow-up analysis of the same patient over several years is
problematic. Thus, there is a clear need to search for
biomarkers in other body fluids (Box 2) to diagnose AD
[13]. Although saliva or urine can be easily collected, blood
analysis is the gold standard (Box 2); yet, it is still unknown
how the concentration of analytes in the blood directly
correlates with pathological changes in the brain, especial-
ly in AD. The search for blood biomarkers that correlate
with AD should therefore begin with accepted CSF mar-
kers, such as Ab and tau-related biomarkers, and further
include factors involved in inflammation, protein aging
and cell death, and cerebrovascular dysfunctions.
Ab-related proteins
Blood plasma levels of Ab are increased in familial AD and
Down syndrome, but results are inconsistent with sporadic
AD [4]. Studies have shown that plasma Ab(1–42) and
Ab(1–40) levels can be elevated, reduced or even un-
changed in AD versus control patients [4,14]. A significant
increase in Ab(1–42) plasma levels has been seen inwomen
with MCI, but not in men, as compared with cognitively
normal, age-matched subjects [25]. Recent longitudinal
studies have shown that high plasma Ab(1–42) levels
are a risk factor for developing AD; however, there is27
Table 3. Selected examples of methods to discover biomarkers for AD diagnosis
Analytical method Description Biomarker Refs.
ELISA Single 96-well assay Ab42, total tau,
phospho-tau-181 (single)
[9,10,12,22]
Multiplex Searchlight ELISAs (Aushon) 16 (chemiluminescence) or 24 (infrared)
markers per single well in 96-well
16 signaling proteins [37]
Filter-based array sandwich ELISA ‘Capture’ antibody is on a filter; requires
detection antibody after antigen capture
18 signaling proteins [36]
INNO-BIA AlzBio3 Luminex-based
technology (Innogenetics)
Liquid bead arrays; xMAP Ab42, total tau, phospho-
tau-181 (multiplex)
[60]
Tissue array Antigen-spotted microarray to detect
auto-antibodies; consists of paraffin blocks
with 1,000 separated tissues for
multiplexed histological analysis
2,325 tissue specimens [69]
Quantitative real-time RT-PCR Amplification of DNA alone or coupled
to immunoassays (immuno-PCR)
33 genes; multiple
phosporylated tau-epitopes
[62,64]
Liquid chromatography/electrospray
ionisation MS
Ab40, Ab42 [66]
Capillary electrophoresis/MS Rapid, 60-min analysis 1000 polypeptides [68]
Ultrasensitive laser ablation inductively
coupled plasma/MS
Trace elements and metal ions [67]
Multiplex iTRAQ Isobaric tagging for relative and
absolute protein quantification
with multi-dimensional
chromatography and tandem MS
1,500 CSF proteins [63]
Surface-enhanced laser
desorption/ionization (SELDI)- or
matrix-assisted laser desorption
/ionization (MALDI)-MS
Time-of-flight (TOF) MS Several Ab species: Ab37,
Ab36, Ab38, Ab40; several
other biomarkers
[19,65,
74–77]
DNA/RNA chips, BioChips, GeneChips Microspots on a matrix with a single,
defined species of nucleic acids
Several thousand genes [70–73]
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early diagnosis [26]. A decrease of serum Ab(1–42) auto-
antibodies has been found in AD [27], yet no correlation
between CSF and plasma Ab levels has been found. Anti-
gen-spotted microarrays could help identify and validate
AD-selective biomarker autoantibodies in blood and CSF.
Such a rapid assay has been developed, which measuresBox 2. Tissue and liquids to screen for biomarkers:
advantages and disadvantages
Biomarkers can be discoverd from different human tissues or liquids.
The analysis of postmortem brain tissue is necessary to verify AD by
immunohistochemical analysis of plaques (Ab) and tangles (tau).
Postmortem analysis or, alternatively, brain biopsies might also allow
screening for general pathological changes in the AD brain, but are
not useful for routine biomarker analysis. CSF is a very useful fluid for
AD diagnosis, because it reflects metabolic processes in the brain
owing to direct contact between the brain and CSF. Its diagnostic use
is only limited because of invasive collection by lumbar puncture.
Plasma/serum measurements are the gold standard in clinics,
because they are minimally invasive, as compared with CSF, and
therefore easily collected and processed. For AD biomarker discovery,
the use of plasma is still limited, because changes are very small and
heterogeneous and plasma/serum data reflect a broad spectrum of
changes; not all necessarily related to AD. A major advantage of blood
samples is that patients can be followed up and screened over several
years. The analysis of blood cells (e.g. peripheral blood mononuclear
cells, lymphocytes, monocytes or platelets) might be more restricted
to specific AD-related pathologies. The disadvantage is the more
complex and time-consuming processing of blood cells, especially
when culturing blood cells under sterile conditions. The collection of
other fluids (e.g. saliva, urine, fibroblasts, or eye secretions) is fast,
cheap and noninvasive; however, the use of these fluids requires very
sensitive methods to detect low-level proteins and the correlation to
AD pathologies is unclear.
28the difference between dissociated sera and the corre-
sponding non-dissociated sera [28].
There are several reasons why plasma levels of Ab(1–
42) are unstable: (i) Ab expression is influenced by medica-
tions [29]; (ii) Ab binds to other proteins and thus becomes
trapped; (iii) Ab levels in blood fluctuate over time and
among individuals, and might differ in mild, early and late
AD; and (iv) blood platelets contain high amounts of Ab,
which directly affects plasma levels. Platelets express APP
and the secretase machinery, and mainly process Ab(1–
40), which plays a role in platelet aggregation. In platelets
of AD patients, three subtypes of APP (106, 110 and 130
kDa) have been found [30,31]. AD patients show enhanced
processing of the 130-kDa APP subtype, which results in a
mean APP form ratio – [130 kDa subtype]/[(106 kDa sub-
type) + (110 kDa subtype)] – of 0.350.18, whereas controls
have amean ratio of>0.83. A cut-off level of>0.6 results in
a sensitivity of 83% and a specificity of 71% when diagnos-
ing AD [30,31].
Autophagic degradation of intracellular components via
the lysosomal pathway is abnormal in AD. Macrophages
and monocytes of AD patients are generally poorly phago-
cytic for Ab, whereas cells of control patients robustly
internalize Ab [32]. Phagocytosis of Ab can be tested using
in vitro differentiated monocytes/macrophages exposed to
fluorescent Ab [32]. Monocytes can be detected by immu-
nofluorescent staining with anti-CD68 and visualized in
flow cytometric tests (e.g. fluorescence-activated cell sort-
ing) or by immunohistochemistry [32].
Enzymes related to tau pathology
Tau is a brain-specific protein, and altered function of
protein kinases and phosphatases has been implicated
Review Trends in Biotechnology January 2011, Vol. 29, No. 1in tau pathology [21]. A number of kinases contribute to
tau hyperphosphorylation, including glycogen synthase
kinase-3 (GSK-3), cyclin-dependent kinase 5, and microtu-
bule affinity-regulating kinase; conversely, protein phos-
phatase 2A dephosphorylates tau. It has been reported
that GSK-3 is significantly increased in white blood cells in
AD and MCI patients, as compared with healthy subjects
[33]. This correlation notwithstanding, reduced GSK-3
levels in peripheral-bloodmononuclear cells have also been
noted in AD patients [34], which indicates high variability.
Protein kinase C (PKC) appears to be altered in fibroblasts,
lymphocytes, and red blood cells of AD patients [35], which
supports the view that PKC conformation in peripheral
cells could be an early predictive marker for AD. At pres-
ent, tau-related biomarkers in the periphery do not seem to
be useful for AD diagnosis.
Inflammatory markers
In the brain of an AD patient, neuroinflammatory process-
es occur, including activation ofmicroglia and expression of
proinflammatory cytokines, which probably contribute to
neuronal cell death. A recent promising study has shown
that the combination of 18 selected biomarkers (chemo-
kines, cytokines, growth factors and binding proteins) in
plasma might allow the diagnosis of AD [36] and MCI with
nearly 90% accuracy. These 18 biomarkers have been
selected from 120 signalling proteins by sandwich ELISAs
(Table 3). Recently, 16 of these 18 biomarkers have been
tested using a similar Multiplex Searchlight ELISA sys-
tem (Aushon: www.aushon.com) (Table 3), but similar
changes could not be confirmed, and furthermore, a lower
sensitivity/specificity of 60% was demonstrated [37]. Simi-
larly, the use of Luminex-based technology (Table 3)
yielded a diagnostic accuracy of only 70% [38]. The Lumi-
nex method differs from conventional ELISAs in the way
that the capture antibody is attached to 5.6-mm polysty-
rene beads, which are internally dyed with fluorophores of
different intensities, and can be detected using dual laser
systems for classification and quantification.
Other disease-related markers
Failure of the ubiquitin–proteasome pathway function has
been linked to Ab toxicity, and indeed ubiquitin levels are
elevated in AD [39]. It is well known that ubiquitin levels
are increased several-fold in the cerebral cortex and CSF of
patients with AD. This increase strongly correlates with
the degree of neurofibrillary changes in the tissue [40,41].
In CD45+ T lymphocytes, the ubiquitin–proteasome path-
way has been found to be reduced during ageing [40]. We
have recently shown that in peripheral blood mononuclear
cells, the enzymes for proteasomal activity (conjugating
and activating enzymes E1 and E2) are changed [42].
Cellular senescence is a stress response phenomenon
that results in functional changes, such as telomere short-
ening [43]. In peripheral blood cells of AD and VaD
patients, shorter telomeres than those in age-matched
controls have been discovered [44–46]. Recently, it has
been reported that fibroblasts from sporadic AD patients
specifically express an anomalous and detectable confor-
mational state of the senescence marker p53 (mutant-like
p53) that allows for differentiation of AD subjects [47].Peripheral blood cells of AD patients are also more sensi-
tive to apoptosis [48–50]. Increased apoptosis has been
noted in CD4+ T cells and natural killer cells of AD
patients, accompanied by enhanced expression of the an-
ti-apoptotic protein B-cell lymphoma 2 (Bcl-2), the antioxi-
dant enzyme superoxide dismutase 1 (SOD1), and different
subtypes of caspases [51,52].
In AD, damage of the cerebrovascular system, including
the blood–brain barrier and neurovascular unit, results in a
loss of energy supply to the brain, accompanied by silent
strokes; thus, measurement of biomarkers associated with
cerebrovascular damage could provide sensitive instru-
ments for the diagnosis of AD. It is well-established that
high concentrations of C-reactive protein (CRP) are predic-
tive of cognitive decline and dementia [53]. Furthermore,
increased plasma homocysteine in combination with de-
creased folate and vitamin B12 are biomarkers for VaD,
and might discriminate between AD and controls [54]. The
analysis of vasodilators or vasoconstrictors (e.g. pro-adre-
nomedullin, pro-atrial natriuretic peptide, C-terminal
endothelin 1 precursor fragment) or cell adhesionmolecules
[vascular cell adhesion molecule (VCAM)-1, intercellular
adhesionmolecule (ICAM)-1, ICAM-3, andP-selectin]might
lead to improved diagnosis of AD [55]. Increased plasma
levels of VCAM-1 and ICAM-1 have been observed in AD
patients [55,56].
Searching for patient-specific, multi-biomarker profile
signatures
The principal goal is to discover biomarkers, with the ulti-
mate objective of identifying differentially expressed pro-
teins between diseased and healthy controls. Novel and fast
high-throughput systems dramatically enhance the analy-
sis of thousandsofproteinsandgenes (Table3)withvery low
volumes. It is becoming clear that the consideration of a
single biomarker might not be potent enough to improve
diagnostic specificity. Thus, it is essential to develop meth-
ods to measure several biomarkers together in a single well
or on a biochip to create an accurate prognostic profile.
DNA and RNAmicroarrays have led to the identification
of multiple genes that appear in early stages of AD [5];
however, DNA/RNA microarrays or transcriptomics (Table
3) aloneprobablyprovideonlya limitedviewof thebiological
process. The combination of genomics and proteomics has
rapidly gained interest, and such interdisciplinary research
will markedly further biomarker discovery [57]. Thus, re-
search needs to develop simple, inexpensive and rapid tools
to measure several biomarkers at the same time. As an
example, a combination of the following biomarkers on a
singleMultiplex Sandwich ELISAMicroarray is a possibili-
ty: five-plex ofmacrophage inflammatory proteins-1d and -4
(MIP1d andMIP4), regulated upon activation normal T-cell
(RANTES) [23], tumor necrosis factor-alpha (TNFa) [37]
and midregional pro-atrial natriuretic peptide (MR-
proANP) [55] in plasma; a three-plex of ICAM-3, P-selectin
and CD14 in monocyte extracts [56]; and a novel four-plex
ELISA of selective APP 130-, 110- and 106-kDa proteins,
including actin as a control from platelet extracts [31]. A
combination of such a 12-plex array could have the potential
to improve AD diagnosis from blood. The development of a
patient-specific chip array could allow us to define specific,29
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Figure 1. The principal steps necessary for AD biomarker discovery (left flowchart)
and for routine analysis of CSF samples (right flowchart). Similar steps are shown
in red boxes. Only a good clinical diagnosis is the basis for statistical analysis of
biomarker discovery. To date, laboratory diagnosis only supports the clinical
diagnosis, which cannot be regarded as a stand-alone diagnostic tool.
Review Trends in Biotechnology January 2011, Vol. 29, No. 1multi-biomarker profile signatures, which could even act as
a prognosticator for AD.
Future challenges and criteria for a good diagnostic
assay
Routine analysis of CSF samples (Figure 1) is well-estab-
lished worldwide; however, a common consensus [58] on
several issues is still missing, and thus the interpreta-
tion and support of clinical diagnosis is still not unique.
It is essential to define routine procedures for: (i) collec-
tion, transport, processing and storage of samples; (ii)
analysis; and (iii) interpretation (diagnosis) and cut-off
values.
Handling of samples (collection, transport, processing
and storage)
It is crucially important to search not only for the biomark-
ers themselves, but also for biomarkers that are stable.
Often, samples are collected by medical doctors outside
hospitals and without a laboratory. They do not have the
time to process or capability to freeze samples. Thus, it is
highly desirable to identify biomarkers with long half-
lives. RNAs are very unstable; therefore, these criteria
largely exclude the use of RNA chips, unless RNA stabi-
lizers are accessible. It also needs to be considered that
several other parameters can influence the stability of a
protein, such as repeated freeze/thaw cycles or long-term30storage at room temperature. Even measurements of pro-
teins in serum or plasma with or without EDTA, heparin,
or citrate can produce variable results for the same bio-
marker. Worldwide multicenter studies are necessary to
compare the diagnostic accuracy in different laboratories
[59].
Analysis
Analytical methods are often limited by cost. Commercial
ELISAs (e.g. Innogenetics: www.innogenetics.be) for Ab,
tau and phospho-tau-181 are very expensive. We have
calculated that a 96-well plate ELISA costs approximately
s900, and threekits are typicallyneeded for quantifyingAb,
total tau and phospho-tau-181. Analysis is performed in
duplicate, and includes a standard curve. In this situation,
the estimated cost is approximatelys68per patient, exclud-
ing personnel and laboratory expendables. Cheaper diag-
nostic methods that cost around s10 per patient are
warranted. Towards this goal, it is necessary to develop a
multiplexedELISA system tomeasure all three biomarkers
concurrently in a single well. The INNO-BIA AlzBio3 assay
(Innogenetics) already allows simultaneous quantification
of all three biomarkers using xMAP Luminex technology
[60].
Another limitation is the analysis of lowly and highly
expressed proteins in the same well. If we want to measure
low-level proteins, then a dilution of 1:2 in the assay might
be required; however, a high-level protein cannot be quan-
tified at such a low dilution in the same well, because it
reaches saturation. Therein lies the need for two separate
assays, which increases the cost associated with diagnosis.
Interpretation and cut-off values
Finally, it is important to provide good interpretation of the
data to support clinical diagnosis. In our experience, a
medical doctor without a background in laboratory experi-
mentation and analysis cannot interpret raw data. Thus,
standardized testing and international cut-off values will
be important.
Validating novel biomarkers in AD diagnosis
In the scientific search for biomarkers (Figure 1), several
additional criteria must be met and standardized: (i)
healthy controls; (ii) clinical diagnosis and verification;
and (iii) publication and validation by multicenter studies.
First, it is important to collect healthy controls who are
age-matched and have a similar lifestyle, sex and educa-
tion. This is extremely difficult to achieve, and might
explain the high variety in the data. The ‘nun-study’ [61]
has tried to overcome this problem by analyzing a well-
defined cohort of people.
Second, in the search for a biomarker, it is important to
have a perfect clinical diagnosis. A medical doctor must
collect all criteria for enabling a correct diagnosis (including
anamnesis, family history, general blood markers, neuro-
psychology, and neuroimaging, excluding other diseases).
Secure diagnosis of AD can only be defined by postmortem
brain analysis. It is worth noting that, to date, CSF diagno-
sis only supports the clinical (not postmortem) diagnosis.
Lastly, the data must be reproduced by others to vali-
date the biomarkers, thus the scientific data must be
Review Trends in Biotechnology January 2011, Vol. 29, No. 1published in well-known, peer-reviewed journals. At least
two independent research studies worldwide should con-
firm the results. Global initiatives, multicenter studies,
and consensus protocols of analysis are of crucial impor-
tance. In this way, there will be evidence that the novel
biomarkers are (or are not) useful in therapeutic studies of
AD and other forms of dementia.
Summary
At present, only the analysis of Ab(1-42), total tau and
phospho-tau-181 in CSF allows reliable, sensitive and
specific diagnosis of AD, but not of other forms of dementia.
Unfortunately, the use of CSF biomarkers is limited be-
cause of invasive collection methods. Efforts are underway
to discover reliable blood biomarkers. To date, it seems
probable that only the combination of several biomarkers
derived from blood will be successful to define a patient-
specific signature. Early, fast and cheap diagnosis from
body fluids using modern, ultrasensitive analytical meth-
ods (e.g. microarrays or MS) will become extremely impor-
tant in the future to differentiate AD from other forms of
dementia, and to gauge therapeutic relevance.
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